オプションチェーンは、Solid Biosciencesの株式オプションの主要データを様々な行使価格と満期日で表示します。トレーダーはこの情報を使用して、潜在的な取引を分析し、Solid Biosciencesの市場センチメントを評価します。.

Solid Biosciences (NASDAQ:SLDB) 株価情報, オプションチェーン

SOLID BIOSCIENCES INC

Solid Biosciences

Solid Biosciences Inc is a life science company. It is engaged in the manufacturing of specialty and generic drugs. The company is involved in curing Duchenne muscular dystrophy (DMD), a genetic muscle-wasting disease predominantly affecting boys, with symptoms that usually manifest between three and five years of age. The company's pipeline products are the SB-001 and solid suit. The Company's singular focus is on developing treatments through gene therapy and other means for patients with neuromuscular and cardiac diseases. The company has categorized its programs into corrective therapies, disease-modifying therapies, and assistive devices.

Solid Biosciences Inc

TherapeuticsMD (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TXMD#NASDAQ">TXMD</a>) reported quarterly losses of $(0.06) per share. This is a 14.29 percent increase over losses of $(0.07) per share from the same period last year. The company reported $393.00 thousand in sales this quarter. This is a 25.56 percent increase over sales of $313.00 thousand the same period last year.

Earnings

News

TXMD

TherapeuticsMD Q1 EPS $(0.06) Up From $(0.07) YoY, Sales $393.00K Up From $313.00K YoY

Sen. Bernie Sanders (I-VT) says American workers are frustrated and they have a good reason to be.&nbsp;
In a recent <a href="https://x.com/BernieSanders/status/1919106487508414676">post on X</a>, Sanders pointed out that despite decades of rising worker productivity, inflation-adjusted wages are lower today than they were 52 years ago. At the same time, he noted a massive transfer of wealth from the bottom 90% to the top 1%, calling the situation unacceptable. "The status quo is NOT working. We need real change," he wrote.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">American workers are angry. Despite increased worker productivity, inflation-adjusted wages are lower today than they were 52 years ago. At the same time, there was a huge transfer of wealth from the bottom 90% to the top 1%. The status quo is NOT working. We need real change.
&mdash; Bernie Sanders (@BernieSanders) <a href="https://twitter.com/BernieSanders/status/1919106487508414676?ref_src=twsrc%5Etfw">May 4, 2025</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
Don't Miss:
<ul class="wp-block-list">
<li>Deloitte's fastest-growing software company partners with Amazon, Walmart &amp; Target – <a href="https://www.benzinga.com/money/mode-mobile-2">Many are rushing to grab 4,000 of its pre-IPO shares for just $0.30/share!</a></li>
<li>Maker of the $60,000 foldable home has 3 factory buildings, 600+ houses built, and big plans to solve housing —<a href="https://www.benzinga.com/money/boxabl"> this is your last chance to become an investor for $0.80 per share.</a></li>
</ul>
<h2 class="wp-block-heading">A Growing Gap Between Productivity and Pay</h2>
The Economic Policy Institute backs up Sanders&#8217; claims. According to a recent EPI <a href="https://www.epi.org/productivity-pay-gap/">report</a>, U.S. productivity has surged by 86.5% from 1979 to 2024, while hourly pay for typical workers only grew by 31.7% over the same period. That means productivity has grown nearly three times faster than wages, creating a wide gap between the value workers produce and what they take home.
The EPI argues this gap is not an accident but a result of policy decisions that reduced worker bargaining power, <a href="https://www.benzinga.com/news/25/01/42918620/unions-should-brace-for-competition-what-trumps-labor-revolution-means-for-workers">weakened unions</a>, and shifted more wealth to capital owners. The report points out that this shift has resulted in slower economic growth overall, with typical workers missing out on the benefits of rising productivity.
"The growing wedge between productivity and typical workers' pay is income going everywhere but the paychecks of the bottom 80% of workers," the EPI said. "If it didn't end up in paychecks of typical workers, where did all the income growth implied by the rising productivity line go? Two places, basically. It went into the salaries of highly paid corporate and professional employees. And it went into higher profits (returns to shareholders and other wealth owners)."
Trending: Nancy Pelosi Invested $5 Million In An AI Company Last Year — <a href="https://www.benzinga.com/money/elf-labs-ym?v=123">Here's How You Can Invest In Multiple Pre-IPO AI Startups With Just $1,000.</a>
<h2 class="wp-block-heading">Longer Hours, Shorter Lives</h2>
Sanders has also recently <a href="https://www.benzinga.com/news/25/03/44302734/bernie-sanders-says-stress-kills-as-he-highlights-a-7-year-life-expectancy-gap-between-the-working-class-and-the-wealthy">raised concerns about the health impact</a> of economic stress. In a recent <a href="https://www.sanders.senate.gov/wp-content/uploads/3.7.2025-Life-Expectancy-Working-Class-Report_final.pdf">report</a> from the Senate Committee on Health, Education, Labor and Pensions, he highlighted a growing life expectancy gap between the wealthy and the working class. The report found that Americans in the wealthiest 1% of counties live an average of 84.3 years, while those in the bottom 50% of counties live only 77.4 years.
One stark example from the report shows that Loudoun County, Virginia, one of the wealthiest counties in the U.S., has a life expectancy of 84 years, while McDowell County, West Virginia, one of the poorest, has a life expectancy of just 69 years—a 15-year difference despite being only about 350 miles apart.
"Stress kills," Sanders said, adding that these disparities are unacceptable in a wealthy country like the U.S. "The massive <a href="https://www.benzinga.com/personal-finance/25/01/43351521/2025-is-the-year-the-wealth-disparity-gets-much-worse-viral-finance-influencer-explains-the-trump-economic-effect">income and wealth inequality</a> that exists in America today is not just an economic issue, it is literally a matter of life and death."
See Also: Shark Tank's Kevin O'Leary called Missing Ring his biggest mistake — Don't repeat history—<a href="https://www.benzinga.com/money/big-tech-has-spent-billions-acquiring-ai-smart-home-startups-one-company-stands-to-benefit-and-has-already-made-10-million">invest in RYSE at just $1.90/share.</a>
<h2 class="wp-block-heading">Closing the Gap</h2>
To address these issues, Sanders has proposed a series of policy changes aimed at boosting workers&#8217; pay and improving their quality of life. These include <a href="https://in.benzinga.com/news/25/04/45028145/joe-rogan-agrees-with-bernie-sanders-saying-hes-right-that-you-should-be-scared-of-oligarchs-they-shouldnt-be-running-the-government">raising the minimum wage to at least $17 an hour</a>, implementing Medicare for All, expanding Social Security, providing paid family leave, and making education more affordable.
Sanders argues that these steps are essential if the U.S. is to close the growing gap between the rich and the working class and ensure that all Americans can share in the nation&#8217;s prosperity.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/money/a-cure-for-osteoarthritis-powered-by-everyday-investors-cytonics-is-looking-to-beat-big-pharma-and-disrupt-a-390-billion-market">Invest Where It Hurts — And Help Millions Heal: Invest in Cytonics and help disrupt a $390B Big Pharma stronghold.</a></li>
<li>‘Scrolling To UBI' — Deloitte's #1 fastest-growing software company allows users to earn money on their phones. <a href="https://www.benzinga.com/money/mode-mobile-2">You can invest today for just $0.30/share with a $1000 minimum.</a></li>
</ul>
Image: Shutterstock

Bernie Sanders Says 'American Workers Are Angry' Because Wages Haven't Kept Up—'They Are Lower Today Than They Were 52 Years Ago'

UMB Financial (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UMBF#NASDAQ">UMBF</a>) has outperformed the market over the past 5 years by 3.2% on an annualized basis producing an average annual return of 17.95%. Currently, UMB Financial has a market capitalization of $8.20 billion. 
Buying $1000 In UMBF: If an investor had bought $1000 of UMBF stock 5 years ago, it would be worth $2,487.10 today based on a price of $107.99 for UMBF at the time of writing.
<h3>UMB Financial's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1747175410_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Trading Ideas

UMBF

$1000 Invested In UMB Financial 5 Years Ago Would Be Worth This Much Today

Flora Growth (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FLGC#NASDAQ">FLGC</a>) reported quarterly losses of $(0.04) per share which beat the analyst consensus estimate of $(0.16) by 75 percent. This is a 89.47 percent increase over losses of $(0.38) per share from the same period last year. The company reported quarterly sales of $11.79 million which missed the analyst consensus estimate of $15.42 million by 23.55 percent. This is a 34.63 percent decrease over sales of $18.03 million the same period last year.

Earnings Beats

Earnings Misses

FLGC

Flora Growth Q1 EPS $(0.04) Beats $(0.16) Estimate, Sales $11.79M Miss $15.42M Estimate

Anebulo Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ANEB#NASDAQ">ANEB</a>) reported quarterly losses of $(0.04) per share which beat the analyst consensus estimate of $(0.05) by 20 percent. This is a 33.33 percent increase over losses of $(0.06) per share from the same period last year.

ANEB

Anebulo Pharmaceuticals Q3 EPS $(0.04) Beats $(0.05) Estimate

Lightwave Logic (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LWLG#NASDAQ">LWLG</a>) reported quarterly losses of $(0.04) per share. This is a 20 percent increase over losses of $(0.05) per share from the same period last year. The company reported $22.92 thousand in sales this quarter. This is a 24.66 percent decrease over sales of $30.42 thousand the same period last year.

LWLG

Lightwave Logic Q1 EPS $(0.04) Up From $(0.05) YoY, Net Sales $22.92K Down From $30.42K YoY

Ambase (OTC:<a class="ticker" href="https://www.benzinga.com/stock/ABCP#OTC">ABCP</a>) reported quarterly losses of $(0.02) per share. This is a 60 percent increase over losses of $(0.05) per share from the same period last year.

ABCP

Ambase Q1 EPS $(0.02) Up From $(0.05) YoY

Satellogic (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SATL#NASDAQ">SATL</a>) reported quarterly losses of $(0.34) per share. This is a 100 percent decrease over losses of $(0.17) per share from the same period last year. The company reported $3.39 million in sales this quarter. This is a 1.77 percent increase over sales of $3.33 million the same period last year.

SATL

CORRECTION: Satellogic Q1 EPS $(0.34) Down From $(0.17) YoY, Sales $3.39M Up From $3.33M YoY

McDonald's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MCD#NYSE">MCD</a>) has outperformed the market over the past 20 years by 3.89% on an annualized basis producing an average annual return of 12.19%. Currently, McDonald's has a market capitalization of $220.59 billion. 
Buying $1000 In MCD: If an investor had bought $1000 of MCD stock 20 years ago, it would be worth $9,967.39 today based on a price of $308.75 for MCD at the time of writing.
<h3>McDonald's's Performance Over Last 20 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1747174516_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Here's How Much $1000 Invested In McDonald's 20 Years Ago Would Be Worth Today

Chardan Capital analyst Keay Nakae maintains Orchestra BioMed Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OBIO#NASDAQ">OBIO</a>) with a Buy and maintains $20 price target.

Price Target

Analyst Ratings

Orchestra BioMed Holdings, Inc. - Ordinary Shares

OBIO

Chardan Capital Maintains Buy on Orchestra BioMed Hldgs, Maintains $20 Price Target

Chardan Capital analyst Keay Nakae maintains Korro Bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KRRO#NASDAQ">KRRO</a>) with a Buy and maintains $25 price target.

KRRO

Chardan Capital Maintains Buy on Korro Bio, Maintains $25 Price Target

General

EXEL

Invenra's Collaboration Partner Exelixis Initiates The Dose-Escalation Stage Of The First-In-Human Phase 1 Clinical Study Of XB628 In Participants With Recurrent Advanced Or Metastatic Solid Tumors

Reality competition "Beast Games"<a href="https://www.benzinga.com/general/entertainment/24/03/37809533/mrbeast-confirms-beast-games-on-amazon-prime-video-with-1-000-contestants-5m-prize-its-gonn"> from the mind of</a> content creator MrBeast is returning for two more seasons on Prime Video, the streaming platform from Amazon.com Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>).
MrBeast says he hopes this time the show doesn't lose him as much money, but he promises to make it bigger than the first season.
What Happened: A first season of "Beast Games" set several records, including 44 Guinness World Records, and had a massive $10 million payout to the winner from 1,000 contestants, but also created a <a href="https://www.benzinga.com/general/entertainment/25/02/43903423/mrbeast-calls-his-amazon-deal-for-beast-games-a-financial-mistake-this-is-the-price-you-have-to-pay">financial loss for MrBeast.</a>
The content creator, also known as Jimmy Donaldson, announced on social media that "Beast Games" has been renewed for two more seasons with Prime Video.
"Y'all are not ready for the big stuff we have planned," MrBeast <a href="https://x.com/MrBeast/status/1922068781058109819">said </a>in the post.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">Prime video has renewed Beast Games for not one but TWO MORE SEASONS!! Y'ALL ARE NOT READY FOR THE BIG STUFF WE HAVE PLANNED &#x1f970;&#x1f970;&#x1f970; <a href="https://t.co/oc5hWKBEnq">pic.twitter.com/oc5hWKBEnq</a>
&mdash; MrBeast (@MrBeast) <a href="https://twitter.com/MrBeast/status/1922068781058109819?ref_src=twsrc%5Etfw">May 12, 2025</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
A user asked MrBeast how he can make the show "go bigger" without the fear of going bankrupt, while asking about his loss on the first season.
"Going bigger is my specialty, that's the least of my concerns haha. Yeah, ideally don't lose 8 figures though," MrBeast replied.
The first season was the most-watched unscripted series on Prime Video, according to a <a href="https://variety.com/2025/tv/news/mrbeast-beast-games-renewed-two-seasons-prime-video-1236392387/">report </a>from Variety. The series had 50 million viewers in the first 25 days after its Dec. 19 premiere.
MrBeast has 32.5 million followers on X and 394 million subscribers on YouTube, ranking as the top followed account on the video platform.
The popularity of the content creator helped boost viewership for Prime Video and could do the same for two more seasons.
Read Also: <a href="https://www.benzinga.com/general/entertainment/24/05/38860861/amazon-betting-on-game-shows-for-streaming-growth-mrbeast-travis-kelce-pop-culture-jeopardy">Amazon Betting On Game Shows For Streaming Growth: MrBeast, Travis Kelce, Pop Culture Jeopardy And More</a>
What's Next: Based on the "Beast Games" <a href="https://www.beastgames.com/">website</a>, it looks like season 2 is still casting. The website says casting is open to people aged 18 or older who can legally travel and re-enter the U.S. for up to six consecutive weeks during the period of May to July 2025.
Contestants must also be free of any obligations including personal, family or work during the designated time period of filming for the show. Another interesting casting nugget is that any current candidates for public office or people intending to run for public office within one year as of July 1, 2026, can not participate in the show.
To get cast on the second season of "Beast Games," contestants need to submit their information along with a one-minute video about themselves that includes answers to some of the following questions:
<ul class="wp-block-list">
<li>"What was your favorite challenge from BEAST GAMES Season 1, and why?</li>
<li>"Who was your favorite contestant from Season 1, and what made them stand out to you?</li>
<li>"What makes you an unforgettable competitor?"</li>
<li>"What would you do with $5,000,000?"</li>
</ul>
Contestants on "Beast Games" are tested with challenges that are physical, mental and social and are also offered bribes to leave the game along the way.
Read Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/25/03/44543735/mrbeast-is-writing-a-squid-game-style-thriller-and-media-companies-are-ready-to-bid-eight-figures-for-the-rights">MrBeast Is Writing A &#8216;Squid Game&#8217; Style Thriller And Media Companies Are Ready To Bid Eight-Figures For The Rights</a></li>
</ul>
Photo: Joe Seer via Shutterstock

Entertainment

Media

AMZN

MrBeast Teases Two More Seasons Of 'Beast Games' After Losing Millions: 'Ideally Don't Lose 8 Figures'

Chardan Capital analyst Keay Nakae maintains Coya Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COYA#NASDAQ">COYA</a>) with a Buy and maintains $14 price target.

COYA

Chardan Capital Maintains Buy on Coya Therapeutics, Maintains $14 Price Target

Mannatech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MTEX#NASDAQ">MTEX</a>) reported quarterly losses of $(0.80) per share. This is a 226.98 percent decrease over earnings of $0.63 per share from the same period last year. The company reported $26.56 million in sales this quarter. This is a 9.63 percent decrease over sales of $29.39 million the same period last year.

MTEX

Mannatech Q1 EPS $(0.80) Down From $0.63 YoY, Sales $26.56M Down From $29.39M YoY

Wells Fargo analyst Yanan Zhu downgrades Affimed (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AFMD#NASDAQ">AFMD</a>) from Overweight to Equal-Weight and lowers the price target from $11 to $0.1.

Downgrades

AFMD

Wells Fargo Downgrades Affimed to Equal-Weight, Lowers Price Target to $0.1

Energous (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WATT#NASDAQ">WATT</a>) reported quarterly losses of $(0.09) per share. This is a 91.89 percent increase over losses of $(1.11) per share from the same period last year. The company reported $343.00 thousand in sales this quarter. This is a 435.94 percent increase over sales of $64.00 thousand the same period last year.

WATT

UPDATE: Energous Q1 Adj. EPS $(0.09) Up From $(1.11) YoY, Sales $343.00K Up From $64.00K YoY

Fifth District Bancorp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FDSB#NASDAQ">FDSB</a>) reported quarterly earnings of $0.02 per share. The company reported $3.20 million in sales this quarter.

FDSB

Fifth District Bancorp Q1 EPS $0.02, Sales $3.20M

Electra Battery Materials (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ELBM#NASDAQ">ELBM</a>) reported quarterly losses of $(0.61) per share. This is a 4.69 percent increase over losses of $(0.64) per share from the same period last year.

ELBM

Electra Battery Materials Q1 EPS $(0.61) Up From $(0.64) YoY

MEI Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MEIP#NASDAQ">MEIP</a>) reported quarterly losses of $(0.39) per share. This is a 71.53 percent increase over losses of $(1.37) per share from the same period last year.

Comments

Solid Biosciences

Solid Biosciences (SLDB) オプション

Solid Biosciences (NASDAQ:SLDB) 株価情報, オプションチェーン

ニュース

パートナーシップ

ベンジンガ・グローバル